Boursorama – Judith Greciet, Onxeo : «AsiDNA could open a new paradigm in cancer treatment»
Read the interview
November 9, 2020 Access management presentation Access live webcast replay
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells […]
American Association for Cancer Research 2020 – Virtual Annual Meeting II The AACR Annual Meeting program covers the latest […]
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]
The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]
Read the article in Le Quotidien du Médecin (in French)
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]
Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]
Read more on BFM Bourse (in French)
Read the article in Les Echos (in French)
Read the article in Cancer Research News
Read the article in La Tribune (in French)
Read the article on clinicalleader.com
First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted […]
Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence […]
Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 […]
Results demonstrate a very strong synergistic effect between AsiDNA™, first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) […]
2 OCT., 2017 PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its […]
Conference Call – Interim results of DRIIV-1 study Access to the replay of the conference call Access to the […]
Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with […]
Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced […]
Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment Acquisition expands […]
Near- and mid term expected milestones Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the […]
Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair […]
Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative […]
Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class […]
The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), […]
New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™ Paris (France), February 13, 2017 […]
Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext […]
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent […]
Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model […]
Paris, October 3, 2018 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
Combination patent to be granted in Europe until 2036 Paris (France), December 18, 2018 – 8.30 pm CET – […]
Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical […]
Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in […]